A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
2022 · Nature Medicine · 355 citations
https://doi.org/10.1038/s41591-022-01969-y
S
Sylvain Choquet
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
502
Papers
12.3K
Citations
57
h-index
155
i10-index
Sylvain Choquet is an academic researcher from Sorbonne Université. The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & CNS Lymphoma Diagnosis and Treatment & Chronic Lymphocytic Leukemia Research. The author has an h-index of 57, co-authored 427 publications.
ORCID: 0000-0002-7791-0470Papers by this author
worksCOVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
2021 · Journal of Hematology & Oncology · 315 citations
https://doi.org/10.1186/s13045-021-01177-0
Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy
2012 · The Pharmacogenomics Journal · 55 citations
https://doi.org/10.1038/tpj.2012.37
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
2025 · Nature Cancer · 36 citations
https://doi.org/10.1038/s43018-025-00921-6
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
2024 · Journal of Hematology & Oncology · 25 citations
https://doi.org/10.1186/s13045-024-01579-w
The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments
2018 · Hematology · 22 citations
https://doi.org/10.1080/10245332.2018.1538001
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat